STUDY: Experimental Pfizer Jab Could Make Recipients More Vulnerable to COVID-19 Variants

How many times do we have to hear Fauci talk about those dreaded variants?

Because of those variants, we don’t know the effectiveness of the experimental jabs.

So, stay at home, social distance, and wear 2-3 face diapers.

Like a good little sheep boy or girl.

I’ve reported on this before here but the Fake News Media continues to blatantly ignore an ominous trend with the global COVID-19 vaccination rollout.

With the exception of a couple outliers, the countries that have vaccinated the most people all witnessed a sudden surge in COVID-19 cases.

Israel, United Kingdom, Serbia, Chile, Hungary, United Arab Emirates are some of the countries to experience this.

Although I’ve noticed this conspicuous trend that the media refuses to discuss, I certainly don’t have the answers.

However, a recent study from Israel may shed some light on the issue.

It appears that recipients of the Pfizer experimental mRNA jab are more susceptible to COVID-19 variants than unvaccinated individuals.

And with those pesky variants running rampant around the world, could more vaccinations lead to more COVID-19 infections?

Does it mean the experimental jabs are causing more harm than good?

Don’t expect the mainstream press to ask that question.

Isn’t that science?

Question, hypothesize, and research to find the answers.

And this new study raises alarming questions regarding the experimental Pfizer jab that warrant further research.

A study in Israel shows people having received 2 doses of the Pfizer vaccine are 8 times more likely to have contracted the South African variant than people who had not been vaccinated. Suggesting that the vaccine may actually result in reduced immunity.https://t.co/liwRdc1Rr9 pic.twitter.com/vRXN8Rp7f7

— Paul Anderson (@PaulAndersonNE6) April 12, 2021

https://twitter.com/HeinzVHoenen/status/1382327159633612811

The coronavirus variant discovered in South Africa can "break through" Pfizer/BioNTech's COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is low and the research has not been peer reviewed.​ https://t.co/sYsuj5rgQh

— Reuters Health (@Reuters_Health) April 11, 2021

From Life Site News:

A new study by Israeli researchers found that a South African variant of COVID may put people who have been vaccinated with the Pfizer-BioNTech vaccine at higher risk of breakthrough infection compared to unvaccinated people.

The study also showed an increased incidence of the UK variant in those who received one dose of the Pfizer shot.

The study, released April 10, reviewed the positive COVID-19 test results of 800 people — 400 people who tested positive for COVID 14 days or more after they received one or two doses of the Pfizer vaccine against 400 unvaccinated people to see if those vaccinated were more likely to be infected with the UK or South African variant compared with unvaccinated individuals.

NATIONAL POLL: Do You Still Have Trump's Back 100%?

The South African variant, B.1.351, was found to make up about 1% of all COVID cases across all the people studied, according to the study by Tel Aviv University and Israel’s largest healthcare provider, Clalit.

But among patients who had received two doses of the vaccine, the variant’s prevalence rate was eight times higher than in those unvaccinated — 5.4% versus 0.7%, Reuters reported.

The research suggests the vaccine is less effective against the South African variant, compared with the original COVID variant and a variant first identified in Britain that had comprised nearly all COVID cases in Israel, researchers said.

“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group,” said Tel Aviv University’s Adi Stern, who headed the research. “This means that the South African variant is able, to some extent, to break through the vaccine’s protection.”

“Based on patterns in the general population, we would have expected just one case of the South African variant, but we saw eight,” Stern told The Times of Israel. “Obviously, this result didn’t make me happy.”

However, Stern said that the sample size was too small to put a figure on its increased ability. “We can say it’s less effective, but more research is needed to establish exactly how much,” she said.